Clinical Trial Update: A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of erlotinib and pertuzumab in relapsed non-small cell lung cancer. The trial is completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Pertuzumab (pertuzumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-05-01